

TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT
(Under 37 CFR 1.97(b) or 1.97(c))

Docket No.
25429/9

In Re Application Of: Reason et al.

OCT 21 2005

Application No.	Filing Date	Examiner	Customer No.	Group Art Unit	Confirmation No.
10/731,550	December 9, 2003	Terra C. Gibbs	21710	1635	4567

Title: DOPAMINERGIC NEURONS DIFFERENTIATED FROM EMBRYONIC CELLS FOR TREATING
NEURODEGENERATIVE DISEASES

Address to:

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

37 CFR 1.97(b)

- The Information Disclosure Statement submitted herewith is being filed within three months of the filing of a national application other than a continued prosecution application under 37 CFR 1.53(d); within three months of the date of entry of the national stage as set forth in 37 CFR 1.491 in an international application; before the mailing of a first Office Action on the merits, or before the mailing of a first Office Action after the filing of a request for continued examination under 37 CFR 1.114.

37 CFR 1.97(c)

- The Information Disclosure Statement submitted herewith is being filed after the period specified in 37 CFR 1.97(b), provided that the Information Disclosure Statement is filed before the mailing date of a Final Action under 37 CFR 1.113, a Notice of Allowance under 37 CFR 1.311, or an Action that otherwise closes prosecution in the application, and is accompanied by one of:

the statement specified in 37 CFR 1.97(e);


OR

the fee set forth in 37 CFR 1.17(p).

TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT
 (Under 37 CFR 1.97(p) or 1.97(c))

Docket No.
 25429/9

In Re Application of: Isaacson et al.



Application No.	Filing Date	Examiner	Customer No.	Group Art Unit	Confirmation No.
10/731,550	December 9, 2003	Terra C. Gibbs	21710	1635	4567

Title: DOPAMINERGIC NEURONS DIFFERENTIATED FROM EMBRYONIC CELLS FOR TREATING NEURODEGENERATIVE DISEASES

Payment of Fee

(Only complete if Applicant elects to pay the fee set forth in 37 CFR 1.17(p))

A check in the amount of _____ is attached.

The Director is hereby authorized to charge and credit Deposit Account No. 50-0369 as described below.

Charge the amount of _____

Credit any overpayment.

Charge any additional fee required.

Payment by credit card. Form PTO-2038 is attached.

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

Certificate of Transmission by Facsimile*

I certify that this document and authorization to charge deposit account is being facsimile transmitted to the United States Patent and Trademark Office (Fa)

 (Date)

 Signature

 Typed or Printed Name of Person Signing Certificate

Certificate of Mailing by First Class Mail

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to "Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450" [37 CFR 1.8(a)] on

10/18/05

(Date)




 Signature of Person Mailing Correspondence

Seema M. Shah

 Typed or Printed Name of Person Mailing Certificate

*This certificate may only be used if paying by deposit account.


 Signature

Dated: 10/18/05

Anthony C. Kuhlmann, Ph.D., Reg. No. 57,147

Attorney for Applicant(s)

Brown Rudnick Berlack Israels LLP

One Financial Center, Box IP

Boston, MA 02111

Tel: (617) 856-8349


Fax: (617) 856-8201

Email: ip@brownrudnick.com

CC:

FORM PTO-1449

INFORMATION DISCLOSURE STATEMENT



ATTY DOCKET NO.

25429/9

SERIAL NO.

10/731,550

APPLICANT(S): Isaacson et al.

FILING DATE:
December 9, 2003ART UNIT:
1635

UNITED STATES PATENT DOCUMENTS

EXAM. INITIAL	DOCUMENT NUMBER	DATE	INVENTOR	CLASS	SUB CLASS	FIL. DATE IF APPR

FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB CLASS	TRAN Y/N

OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)

	Sakurada et al. "Nurr1, an orphan nuclear receptor, is a transcriptional activator of endogenous tyrosine hydroxylase in neural progenitor cells derived from the adult brain." Development, 1999 Vol. 126:4017-4026.
	Bjorklund et al. "Embryonic stem cells develop into functional dopaminergic neurons after transplantation in a Parkinson rat model." Proc. Natl. Acad. Sci., 2002 Vol. 99:2344-2349
	Ramsden et al. "The aetiology of idiopathic Parkinson's disease." Journal of Clinical Pathology: Molecular Pathology; 2001 Vol. 54:369-380.
	Attisano et al. Signal Transduction by the TGF-beta Superfamily. Science, 2002 Vol. 296:1646-1647.

Examiner:

Date: